A potential effect of rh-BMP2 on P53 gene expression in the proceeding oral squamous cell carcinoma In Hamsters

khaled zaid, charif barakat, rashad murad, nour abou qersh, mansour chantiri


Bone morphogenetic proteins (BMPs), belonging to the transforming growth factor-β superfamily, regulate many cellular activities. The Use of recombinant human bone morphogenic protein‑2 (rhBMP‑2) in oral and maxillofacial surgery has seen a tremendous increase, yet the relation between rh-BMP2 and oral squamous cell carcinoma cells (OSCC) is not fully clear.
This study aimed to investigate the effect of rh-BMP2 on p53, a tumor suppressor gene, which is reported to be the most frequent target for genetic alterations leading to cancer during the progression of OSCC in the golden Syrian hamster Buccal pouches.
Materials and methods: Buccal pouches of 34 hamsters were painted with 0.5% DMBA in liquid paraffin three times per week for 14 weeks. 0.25µg of rhBMP-2 were injected in the 1st, 7th and 49th days in the Test group (BMP2 group: 17 hamsters), then biopsies were extracted. Expression of P53 was immunohistochemically investigated in the cancerous tissues.
Results: p53 expression was noticed in 33.11% of "BMP2 group" samples and in 23.19% of "control group" samples, a valuable statistical difference was noticed P<0.05between the two groups.
Conclusion: 0.25µg of rhBMP-2 affects clearly on p53 expression within OSCC cells. BMPs should not be utilized in the presence of a developed oral cancer till more investigations clarify its fully roles and functions in this type of malignancies.

Full Text:



Asgari M, Nabi Maybodi M, Abolhasani M (2016). Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran, 30, 400.

Blanco Calvo M, Bolos Fernandez V, Medina Villaamil V, et al (2009). Biology of BMP signalling and cancer. Clin Transl Oncol, 11, 126-37.

Carreira AC, Alves GG, Zambuzzi WF, et al (2014). Bone Morphogenetic Proteins: structure, biological function and therapeutic applications. Arch Biochem Biophys, 561, 64-73.

Cuellar A, Inui A, James MA, et al (2014). Immunohistochemical Localization of Bone Morphogenetic Proteins (BMPs) and their Receptors in Solitary and Multiple Human Osteochondromas. J Histochem Cytochem, 62, 488-98.

Cuevas Gonzalez JC, Gaitan Cepeda LA, Borges Yanez SA, et al (2016). p53 and p16 in oral epithelial dysplasia and oral squamous cell carcinoma: A study of 208 cases. Indian J Pathol Microbiol, 59, 153-8.

Ebara S, Nakayama K (2002). Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine (Phila Pa 1976), 27, S10-5.

Ebert MP, Yu J, Hoffmann J, et al (2003). Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol, 21, 1708-14.

Farhadieh RD, Smee R, Rees CG, et al (2009). Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. ANZ J Surg, 79, 48-54.

Friedrichs M, Wirsdoerfer F, Flohe SB, et al (2011). BMP signaling balances proliferation and differentiation of muscle satellite cell descendants. BMC Cell Biol, 12, 26.

Granjeiro JM, Oliveira RC, Bustos-Valenzuela JC, et al (2005). Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res, 38, 1463-73.

Hogmo A, Lindskog S, Lindholm J, et al (1998). Preneoplastic oral lesions: the clinical value of image cytometry DNA analysis, p53 and p21/WAF1 expression. Anticancer Res, 18, 3645-50.

Khattak F, Haseeb M, Fazal S, et al (2017). Mathematical Modeling of E6-p53 interactions in Cervical Cancer. Asian Pac J Cancer Prev, 18, 1057-61.

Krishna A, Singh RK, Singh S, et al (2014). Demographic risk factors, affected anatomical sites and clinicopathological profile for oral squamous cell carcinoma in a north Indian population. Asian Pac J Cancer Prev, 15, 6755-60.

Kudo Y, Takata T, Ogawa I, et al (1999). Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep, 6, 539-45.

Lee KB, Folger JK, Rajput SK, et al (2014). Temporal regulation of mRNAs for select bone morphogenetic proteins (BMP), BMP receptors and their associated SMAD proteins during bovine early embryonic development: effects of exogenous BMP2 on embryo developmental progression. Reprod Biol Endocrinol, 12, 67.

Lingen MW, Chang KW, McMurray SJ, et al (2000). Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck, 22, 328-35.

Mesaeli N, Phillipson C (2004). Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells. Mol Biol Cell, 15, 1862-70.

Miyahara H, Yane K, Naitoh H, et al (1997). p53 tumor suppressor gene and ras oncogene mutations in hypopharyngeal squamous cell carcinomas. Int J Oncol, 11, 133-7.

Miyata M, Furukawa M, Takahashi K, et al (2001). Mechanism of 7,12-dimethylbenz[a]anthracene-induced immunotoxicity: role of metabolic activation at the target organ. Jpn J Pharmacol, 86, 302-9.

Ndoye A, Dolivet G, Hogset A, et al (2006). Eradication of p53-mutated head and neck squamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization. Mol Ther, 13, 1156-62.

Rosa EA, Lia EN, Macedo SB, et al (2015). In situ carcinoma developed over oral lichen planus: a case report with analysis of BUB3, p16, p53, Ki67 and SOX4 expression. J Appl Oral Sci, 23, 442-7.

Sarkar J, Dominguez E, Li G, et al (2014). Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog, 53, 648-58.

Sawair F, Hassona Y, Irwin C, et al (2016). p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence. Asian Pac J Cancer Prev, 17, 1243-9.

Solomon MC, Vidyasagar MS, Fernandes D, et al (2016). The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study. Med Oncol, 33, 138.

Swaminathan U, Joshua E, Rao UK, et al (2012). Expression of p53 and Cyclin D1 in oral squamous cell carcinoma and normal mucosa: An Immunohistochemical study. J Oral Maxillofac Pathol, 16, 172-7.

Urist MR (1965). Bone: formation by autoinduction. Science, 150, 893-9.

Yuen PW, Chow V, Choy J, et al (2001). The clinicopathologic significance of p53 and p21 expression in the surgical management of lingual squamous cell carcinoma. Am J Clin Pathol, 116, 240-5.

Zaid KW, Chantiri M, Bassit G (2016). Recombinant Human Bone Morphogenetic Protein-2 in Development and Progression of Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev, 17, 927-32.

DOI (PDF (FULL TEXT)): http://dx.doi.org/10.31557/APJCB.2018.3.1.11


  • There are currently no refbacks.

Copyright (c) 2017 Asian Pacific Journal of Cancer Biology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.





Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention